Search

Displaying results 2721 - 2730 of 10000 in total
  1. Drug

    Gadoversetamide

    go.drugbank.com/drugs/DB00538
    Approved

    Gadoversetamide, marketed under the trade name OptiMARK, is a gadolinium compound used as a contrast agent in magnetic resonance imaging (MRI), particularly imaging of the brain, spine and liver.

    Categories: Compounds used in a research, industrial, or household settingProducts: OPTIMARK 500 MIKROMOL/ML IV. ENJ. ICIN COZ. ICEREN FLAKON, 15 ML, OPTIMARK 500 MIKROMOL/ML IV. ENJ. ICIN COZELTI ICEREN KUL.HAZIR SIRINGA, 15 ML
  2. Drug

    Fludeoxyglucose (18F)

    go.drugbank.com/drugs/DB09502
    ApprovedInvestigational

    Fludeoxyglucose F 18 Injection is a positron emitting radiopharmaceutical containing no-carrier added radioactive 2-deoxy-2-[18F]fluoro-D-g1ucose, which is used for diagnostic purposes in conjunction with … It is administered by intravenous injection.

    Synonyms: Fluorine-18 2-Fluoro-2-deoxy-D-Glucose, 18-F FDGCategories: Compounds used in a research, industrial, or household setting
  3. Drug

    Lacosamide

    go.drugbank.com/drugs/DB06218
    ApprovedInvestigational

    [A262681] Lacosamide was first approved by the European Commission in August 2008 and was later approved by the FDA in October 2008. … [A262681] It was granted approval by Health Canada in September 2010.[L49206]

    Mixtures: ELEPSİ 50 MG+100 MG TEDAVİYE BAŞLAMA PAKETİ, 42 ADET, ELEPSİ 50 MG+100 MG TEDAVİYE BAŞLAMA PAKETİ, 42 ADETCategories: Cytochrome P-450 Substrates, Cytochrome P-450 CYP3A Substrates
  4. Drug

    Vericiguat

    go.drugbank.com/drugs/DB15456
    ApprovedInvestigational

    Vericiguat is a direct stimulator of soluble guanylate cyclase (sGC) used in the management of systolic heart failure to reduce mortality and hospitalizations. … activity in heart failure.

    Categories: Vasodilators Used in Cardiac Diseases, P-glycoprotein substratesProducts: VERQUVO 5 MG FİLM KAPLI TABLET , 14 ADET, VERQUVO 5 MG FİLM KAPLI TABLET , 28 ADET
  5. Drug

    Methocarbamol

    go.drugbank.com/drugs/DB00423
    ApprovedInvestigationalVet approved

    Methocarbamol was developed in the early 1950s as a treatment for muscle spasticity and the associated pain.[A178441,A178450] It is a guaiacol glyceryl ether. … [L6295] A combination product with [acetylsalicylic acid] and [codeine] is available in Canada by prescription.[L6295] Methocarbamol was FDA approved on 16 July 1957.[L6265]

    Mixtures: MIYOREL 375 MG/300 MG TABLET, 20 ADET, METOCARBAMOL 500 MG + IBUPROFENO 200 MG TABLETAS RECUBIERTASSynonyms: (RS)-2-hydroxy-3-(2-methoxyphenoxy)propyl carbamate
  6. Drug

    Ferric ammonium citrate

    go.drugbank.com/drugs/DB09501
    ApprovedWithdrawn

    Mixtures: Iron, Vit & Min SuppProducts: FOLITON 250 MG/5 ML ŞURUP, 120 ML, KİNAMALT SİROP, 250 G
  7. Drug

    Tapentadol

    go.drugbank.com/drugs/DB06204
    ApprovedInvestigational

    Tapentadol is a centrally-acting synthetic analgesic with a dual mechanism of action. It is a mu-opioid receptor agonist that also inhibits norepinephrine reuptake. … [L47291] Used in the management of pain, tapentadol is typically reserved for patients who have limited alternative treatment options.

    Categories: Cytochrome P-450 Substrates, Cytochrome P-450 CYP2C9 SubstratesSynonyms: 3-[(1R,2R)-3-(Dimethylamino)-1-ethyl-2-methylpropyl]phenol, PHENOL, 3-((1R,2R)-3-(DIMETHYLAMINO)-1-ETHYL-2-METHYLPROPYL)-
  8. Drug

    Belimumab

    go.drugbank.com/drugs/DB08879
    ApprovedInvestigational

    It is produced by recombinant DNA technology in a murine cell (NS0) expression system. … [L42630] Belimumab was first approved by the FDA on March 9, 2011,[A251495] making it the newest drug to be approved for the treatment of SLE in more than 50 years.

    Categories: Decreased B Lymphocyte Activation, B Lymphocyte Stimulator-specific InhibitorProducts: BENLYSTA 400 MG IV INFUZYONLUK COZETI HAZIRLAMAK ICIN TOZ ICEREN FLAKON, 1 ADET, BENLYSTA 120 MG IV INFUZYONLUK COZELTI HAZIRLAMAK ICIN TOZ ICEREN FLAKON, 1 ADET
  9. Drug

    Erdafitinib

    go.drugbank.com/drugs/DB12147
    ApprovedInvestigational

    [L5956, L5959] Considering urothelial cancer is statistically the fourth most common kind of cancer in the world, the introduction of erdafitinib offers a much-needed new option in the ever-expanding therapeutic … In early April of 2019, the US FDA approved Janssen Pharmaceutical Companies' brand name Balversa (erdafitinib) as the first-ever fibroblast growth factor receptor (FGFR) kinase inhibitor indicated for

    Categories: Cytochrome P-450 CYP2C9 Substrates with a Narrow Therapeutic Index, P-glycoprotein substrates with a Narrow Therapeutic IndexProducts: BALVERSA 5 MG FİLM KAPLI TABLET, 28 ADET, BALVERSA 3 MG FİLM KAPLI TABLET, 56 ADET
  10. Drug

    Mavacamten

    go.drugbank.com/drugs/DB14921
    ApprovedInvestigational

    It received initial US FDA approval in 2022, and it is one of the first myosin inhibitors to be used in humans. … Mavacamten is a myosin inhibitor indicated for the treatment of adults with symptomatic New York Heart Association (NYHA) class II-III obstructive hypertrophic cardiomyopathy (HCM).

    Categories: Cytochrome P-450 CYP2B6 Inducers, Cytochrome P-450 SubstratesSynonyms: 6-(((1S)-1-Phenylethyl)amino)-3-(propan-2-yl)-1,2,3,4 tetrahydropyrimidine-2,4-dione